** WuXi XDC Cayman 2268.HK rises 4.4% to HK$30.75; set for a second straight session of gains
** Chinese antibody drug developer sees 2024 rev, net profit and adjusted net profit jumping more than 85%, 260% and 170% y/y, respectively, on demand from antibody drug conjugate and bioconjugate industries
** Profit margin improving on high utilisation rate of co's production facilities; faster ramp-up of production lines also increases operating efficiency
** Stock third biggest pct gainer on Hong Kong's healthcare index .HSCIH, which is down 0.7%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。